Comparing Semaglutide vs Tirzepatide for Weight Loss in Adults with Obesity: JAMA Study
In a study published in the journal JAMA Internal Medicine, researchers analysed how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population of adults with overweight or obesity.
Overweight and obesity are common conditions linked to higher risks of various health issues and early death. Traditional weight loss medications have been few, poorly tolerated, and only mildly effective. However, newer drugs like semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GLP-1/GIP agonist, have shown significant weight loss benefits in clinical trials for people with obesity, with or without type 2 diabetes (T2D). While tirzepatide has been found to cause more weight loss than semaglutide in T2D patients, direct comparisons of their effectiveness in people with overweight or obesity are still lacking.
In this cohort study, researchers used electronic health records (EHR) to assess weight outcomes for adults with overweight or obesity who received semaglutide or tirzepatide between May 2022 and September 2023. They included adults with no prior use of GLP-1 receptor agonists, who had regular care in the year before starting the medication, and an available baseline weight. Participants had a BMI of 27 or higher or a diagnosis code for overweight or obesity.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.